NKX019

Phase 1Cell therapy

NNkarta, Inc.

NKX019 is one of 79 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Autoimmune DiseaseActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Autoimmune DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Eptanemab

UCB

Phase 3

12 2

Medrol

Pfizer

Phase 3

5 3

Rinvoq

AbbVie

Phase 3

3 4

Ocrevus

Roche

Phase 3

2 5

Gazyva

Roche

Phase 3

2 6

Cytoxan

BBaxter Healthcare Corporation

Phase 3

11 7

Depo-Provera

Benadryl

3 9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

3 10

Imuran

LLegacy Health System

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Autoimmune Disease

NCT06557265

Q4 2028

Phase 1/2Recruiting

Immune-Mediated Diseases

NCT06733935

Q4 2038

Phase 1Active, not recruiting

Natural Killer Cell

NCT05020678

Clinical

Trials by Indication[1]

Immune-mediated Diseases1 trial

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Recruiting·NNkarta, Inc.·Phase 1/2·NCT06733935·144 enrolled

Autoimmune Disease1 trial

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Recruiting·NNkarta, Inc.·Phase 1/2·NCT06557265·96 enrolled

Natural Killer Cell1 trial

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Active, not recruiting·NNkarta, Inc.·Phase 1·NCT05020678·150 enrolled

Systemic Lupus Erythematosus1 trial

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Systemic Lupus Erythematosus

Enrolling by invitation·HHospital for Special Surgery, New York·Phase 1·NCT06518668·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for NKX019. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NKX019 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NKX019. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nkarta, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: NNkarta, Inc.

NKX019

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Q4 2038

Trials by Indication[1]

Immune-mediated Diseases1 trial

Autoimmune Disease1 trial

Natural Killer Cell1 trial

Systemic Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News